41 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kd inhibitors.
Astrazeneca
Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-ß hydrolysis.
University of Lille
Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual ACE/NEP inhibitors.
Dipartimento Di Chimica
Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells.
University Institute of Pathology
Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action.
Novartis Institute For Biomedical Research
Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents.
F. Hoffmann-La Roche
Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme.
Novartis Pharmaceuticals
Hydroxamic acids as potent inhibitors of endothelin-converting enzyme from human bronchiolar smooth muscle.
Berlex Laboratories
Potent and selective inhibitors of an aspartyl protease-like endothelin converting enzyme identified in rat lung.
Abbott Laboratories
Phosphorus-containing inhibitors of endothelin converting enzyme: effects of the electronic nature of phosphorus on inhibitor potency.
Monsanto
Design, synthesis and biological activity of novel non-peptidyl endothelin converting enzyme inhibitors, 1-phenyl-tetrazole-formazan analogues.
Sumitomo Pharmaceuticals
Potent non-peptidic dual inhibitors of endothelin-converting enzyme and neutral endopeptidase 24.11
TBA
Design and synthesis of phosphinic acids that triply inhibit endothelin converting enzyme, angiotensin converting enzyme and neutral endopeptidase 24.11
TBA
Aminophosphonate endothelin converting enzyme inhibitors: potency-enhancing and selectivity-improving modifications of phosphoramidon
TBA
Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors.
Cea
Non-peptidic inhibitors of neutral endopeptidase 24.11 2. Design and pharmacology of orally active phosphonate prodrugs
TBA
Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder. Synthesis and activity of functionalized glutaramides.
Pfizer
Novel, selective indole-based ECE inhibitors: lead optimization via solid-phase and classical synthesis.
Bayer Healthcare
Synthesis and biological activity of potent heterocyclic thiol-based inhibitors of endothelin-converting enzyme-1.
Novartis Institute For Biomedical Research
N-[2-(Indan-1-yl)-3-mercapto-propionyl] amino acids as highly potent inhibitors of the three vasopeptidases (NEP, ACE, ECE): In vitro and In vivo activities.
University of Paris
Synthesis of triazole-Tethered pyrrolidine libraries: novel ECE inhibitors.
F. Hoffmann-La Roche
2-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)- and 2-(2,2-dioxo-1,4-dihydro-2H-2lambda6-benzo[1,2,6]thiadiazin-3-yl)-N-hydroxy-acetamides as potent and selective peptide deformylase inhibitors.
F. Hoffmann-La Roche
Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases.
Qpex Biopharma
Synthesis and biological activity of novel potent endothelin-converting enzyme-1 inhibitors.
Novartis Institute For Biomedical Research
Discovery of Fluoromethylketone-Based Peptidomimetics as Covalent ATG4B (Autophagin-1) Inhibitors.
Roche Pharma Research and Early Development
Design and synthesis of potent thiol-based inhibitors of endothelin converting enzyme-1.
Novartis Institute For Biomedical Research
Synthesis of a phostone glycomimetic of the endothelin converting enzyme inhibitor phosphoramidon.
Université
Synthesis of novel substituted pyridines as inhibitors of endothelin converting enzyme-1 (ECE-1).
Warner-Lambert
Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.
Shionogi
8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives
Idorsia Pharmaceuticals